Savient partnering with Swedish firm to market arthritis treatment

Select Region or Brand

Business
Legal
- Arizona
- Maryland
- Massachussetts
- Michigan
- Minnesota
- Missouri
- New York
- North Carolina
- Rhode Island
- South Carolina
- Virginia
- Wisconsin
Construction
- Milwaukee, WI
- Oregon
Home Furnishings

Manage account
- Manage Your Print or Online Subscription
- Manage Your Email Subscriptions

Upcoming Event

NJBIZ Leaders in Finance 2023

Free Newsletter Subscribe

News
Events
Power Lists
Leads & Data Center
Conversations
Advertise
Digital Edition
Digital Edition

News
- Education
- Energy
- Food & Hospitality
- Government
- Health Care
- Law
- Manufacturing
- Money
- Real Estate
- Retail
- Technology
- Transportation
Sections
Advertising
Leads & Data
Power Lists

Savient partnering with Swedish firm to market arthritis treatment

Jessica Perry//February 19, 2013

Home>News>

Savient partnering with Swedish firm to market arthritis treatment

Jessica Perry//February 19, 2013

Savient Pharmaceuticals Inc., in Bridgewater, announced today it is partnering with Sobi, of Stockholm, to promote Kineret, a treatment for rheumatoid arthritis, in the United States.Savient is a specialty biopharmaceutical company that has developed and commercialized the gout treatment Krystexxa, which it continues to market.
According to the announcement, Sobi has granted Savient the exclusive rights to co-promote the sale of Kineret with Sobi in the United States. Sobi will remain responsible for all Kineret commercial drug manufacturing, supply, safety and regulatory activities.